Q-omics provides the consensus-scored NTNG2 profile across patient tissues and cancer cell-line models. NTNG2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, NTNG2 is differentially expressed in 11, with the highest sampling consensus in COAD. Additionally, NTNG2 RNA expression shows 19,201 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, COAD, and GBM as cancer lineages where NTNG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTNG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTNG2 survival associations across molecular data types. NTNG2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTNG2 RNA expression–survival associations across cancer types. High NTNG2 expression shows unfavorable associations in ACC, UVM and KIRC, but favorable associations in LGG, LUAD and HNSC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for NTNG2 RNA expression.
This table summarizes NTNG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for NTNG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTNG2 shows higher tumor expression in COAD, KIRC, BRCA, HNSC, STAD and CHOL. The COAD box plot shows higher NTNG2 RNA expression in tumor versus normal tissue (log2 FC = +0.412, t-test p < 0.001).
This table shows molecular features associated with NTNG2 in patient tissues and cancer cell lines. In patient samples, NTNG2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, NTNG2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Leukemia, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and LARGE_INTESTINE.
